Biodesix, which provides diagnostic tests and services for lung disease and other unmet needs, raised $72 million by offering 4 million shares at $18, the midpoint of its range of $17 to $19. The company had originally filed to offer 4.2 million shares.
The company provides data-driven diagnostic solutions to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease. It operates through two segments, diagnostic tests (78% of 1H20 revenue) and diagnostic services (22%). Biodesix currently has four diagnostic blood-based tests across the lung cancer continuum of care.
Biodesix plans to list on the Nasdaq under the symbol BDSX. Morgan Stanley, William Blair, Canaccord Genuity and BTIG acted as joint bookrunners on the deal.
